{"entity":{"id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","aka":[],"tldr":"Joohyuk Sohn is a Yonsei breast oncologist and investigator on the DESTINY-Breast and TROPION trials.","summary":"Joohyuk Sohn is Professor of Medical Oncology at Severance Hospital, Yonsei University, in Seoul, specialising in breast cancer. He leads breast medical oncology trials at Yonsei Cancer Center and has been an investigator on the DESTINY-Breast trials of trastuzumab deruxtecan and the TROPION trials of datopotamab deruxtecan, bringing Korean cohorts into HER2-low, TROP2 antibody-drug conjugate and CDK4/6 studies. His publications include work on cMET activation and resistance to EGFR-directed therapy in triple-negative breast cancer, the D-CARE trial of adjuvant denosumab in early breast cancer, and a phase 3 trial of polymeric micelle-formulated paclitaxel in HER2-negative breast cancer. His interests are HER2-low disease and antibody-drug conjugates.","asOf":"2026-09-08","links":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sohn%20J%5BAuthor%5D%20Yonsei%20breast%20cancer"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2","trop2"],"drugs":["trastuzumab-deruxtecan","datopotamab-deruxtecan"],"companies":[],"institutions":["severance"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-research-and-treatment"],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; breast cancer","institutionId":"severance","specialisms":["Breast cancer","HER2-low","Antibody-drug conjugates"],"profiles":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sohn%20J%5BAuthor%5D%20Yonsei%20breast%20cancer"}],"papers":[{"title":"cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer","journal":"Journal of Cancer","year":2014,"doi":"10.7150/jca.9696"},{"title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","journal":"The Lancet Oncology","year":2020,"doi":"10.1016/s1470-2045(19)30687-4"},{"title":"An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer","journal":"Cancer Research and Treatment","year":2017,"doi":"10.4143/crt.2016.289"},{"title":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2203690","doi":"10.1056/NEJMoa2203690"},{"title":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESTINY-Breast06+trastuzumab+deruxtecan+HER2-low+chemotherapy-naive"},{"title":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","journal":"Journal of Clinical Oncology","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=monarchE+abemaciclib+adjuvant+Johnston+2020"}]},"route":"/people/sohn-joohyuk/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"institution":[{"id":"severance","kind":"institution","name":"Severance Hospital, Yonsei University","route":"/institutions/severance/"}],"journal":[{"id":"cancer-research-and-treatment","kind":"journal","name":"Cancer research and treatment","route":"/journals/cancer-research-and-treatment/"}],"paper":[{"id":"paper-destiny-breast04-nejm-2022","kind":"paper","name":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","route":"/key-papers/paper-destiny-breast04-nejm-2022/"},{"id":"paper-destiny-breast06-nejm-2024","kind":"paper","name":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","route":"/key-papers/paper-destiny-breast06-nejm-2024/"},{"id":"paper-monarche-jco-2020","kind":"paper","name":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","route":"/key-papers/paper-monarche-jco-2020/"}]}}